9.86
0.02 (0.20%)
| Previous Close | 9.84 |
| Open | 9.69 |
| Volume | 383,533 |
| Avg. Volume (3M) | 1,019,748 |
| Market Cap | 1,754,882,688 |
| Price / Book | 4.92 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.72 |
| Total Debt/Equity (MRQ) | 0.95% |
| Current Ratio (MRQ) | 17.23 |
| Operating Cash Flow (TTM) | -198.33 M |
| Levered Free Cash Flow (TTM) | -133.95 M |
| Return on Assets (TTM) | -37.75% |
| Return on Equity (TTM) | -77.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Neumora Therapeutics, Inc. | Mixed | Bullish |
Stockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.75 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 28.00% |
| % Held by Institutions | 61.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Iconiq Capital, Llc | 30 Sep 2024 | 3,398,628 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 30 Sep 2024 | 3,309,123 |
| Johnson & Johnson | 30 Sep 2024 | 1,849,445 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 204.26%) | Buy |
| Median | 26.00 (163.69%) | |
| Low | 15.00 (JP Morgan, 52.13%) | Hold |
| Average | 24.25 (145.94%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 11.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2024 | 30.00 (204.26%) | Buy | 10.78 |
| 01 Oct 2024 | 30.00 (204.26%) | Buy | 13.50 | |
| Needham | 13 Nov 2024 | 23.00 (133.27%) | Buy | 10.78 |
| 18 Oct 2024 | 23.00 (133.27%) | Buy | 16.49 | |
| JP Morgan | 05 Nov 2024 | 15.00 (52.13%) | Hold | 11.91 |
| RBC Capital | 04 Sep 2024 | 29.00 (194.12%) | Buy | 10.99 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2024 | Announcement | Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update |
| 06 Nov 2024 | Announcement | Neumora Therapeutics to Participate in Upcoming Conferences in November |
| 29 Oct 2024 | Announcement | Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |